GeneDx Holdings Corp’s recent filing unveils that its CHIEF FINANCIAL OFFICER Feeley Kevin unloaded Company’s shares for reported $91848.0 on Jun 09 ’25. In the deal valued at $72.55 per share,1,266 shares were sold. As a result of this transaction, Feeley Kevin now holds 5,301 shares worth roughly $0.35 million.
Then, Stueland Katherine sold 3,639 shares, generating $264,009 in total proceeds. Upon selling the shares at $72.55, the Chief Executive Officer now owns 6,348 shares.
Before that, Kevin Feeley bought 5,009 shares. GeneDx Holdings Corp shares valued at $363,400 were divested by the Officer at a price of $72.55 per share.
Guggenheim initiated its GeneDx Holdings Corp [WGS] rating to a Buy in a research note published on May 15, 2025; the price target was $88. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in early May from “a Hold” to “a Buy”. Wells Fargo began covering WGS with “an Equal weight” recommendation on August 28, 2024. Craig Hallum started covering the stock on July 10, 2024. It rated WGS as “a Buy”.
Price Performance Review of WGS
On Monday, GeneDx Holdings Corp [NASDAQ:WGS] saw its stock jump 3.59% to $66.89. Over the last five days, the stock has lost -7.64%. GeneDx Holdings Corp shares have fallen nearly -12.98% since the year began. Nevertheless, the stocks have risen 145.18% over the past one year. While a 52-week high of $117.75 was reached on 04/29/25, a 52-week low of $24.91 was recorded on 05/08/25.
Levels Of Support And Resistance For WGS Stock
The 24-hour chart illustrates a support level at 64.67, which if violated will result in even more drops to 62.46. On the upside, there is a resistance level at 68.02. A further resistance level may holdings at 69.16.
